SBHMY (Sino Biopharmaceutical) Sale Of Business : $252 Mil (TTM As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical Sale Of Business?

Sino Biopharmaceutical's sale of business for the six months ended in Jun. 2024 was $194 Mil. It means Sino Biopharmaceutical gained $194 Mil from selling business. Sino Biopharmaceutical's sale of business for the trailing twelve months (TTM) ended in Jun. 2024 was $252 Mil.

Compared with last quarter ($58 Mil in Dec. 2023 ), Sino Biopharmaceutical gained more money from selling business in Jun. 2024 ($194 Mil).

Sino Biopharmaceutical Sale Of Business Historical Data

The historical data trend for Sino Biopharmaceutical's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Sale Of Business Chart

Sino Biopharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Sale Of Business

Get a 7-Day Free Trial

57.96

Sino Biopharmaceutical Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Sale Of Business	Get a 7-Day Free Trial															-	0.06	57.89	194.31	-

Sino Biopharmaceutical Sale Of Business Calculation

The amount earned to sell business.

Sale Of Business for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $252 Mil.

Sino Biopharmaceutical Sale Of Business Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » Sale Of Business

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.